Jae Kim, MD

Chief Medical Officer

Jae Kim, MD, is the Chief Medical Officer at Septerna. Dr. Kim is an accomplished healthcare executive with extensive experience in advancing novel therapies across multiple therapeutic areas.

Dr. Kim previously served as Chief Medical Officer at Design Therapeutics, where he led the clinical advancement of the company’s pipeline of small molecule genomic therapeutics. Earlier, he served as Chief Medical Officer at Avidity Biosciences, Vice President of Clinical Development at Alnylam Pharmaceuticals, and before that, he held roles of increasing responsibility in global development at MyoKardia and Amgen. Dr. Kim has contributed to the development and/or approval of multiple drugs including Givlaari (givosiran), Amvuttra (vutrisiran), Leqvio (inclisiran), Camzyos (mavacamten), Corlanor (ivabradine), and Repatha (evolcumab).

Dr. Kim is a board-certified cardiologist, and his academic career included serving on the Faculty of Medicine at Harvard Medical School and the Brigham and Women’s Hospital. He earned his BA in Biological Sciences from Cornell University and his MD from Cornell University Medical College, completed a post-doctoral fellowship in Genetics at Harvard Medical School, and completed clinical training in cardiovascular disease at the Brigham and Women’s Hospital and Massachusetts General Hospital.